16 stem cells and cellular plasticity Flashcards

1
Q

What is a stem cell?

A

An undifferentiated cell capable of indefinite self-renewal and differentiation into other cell types.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the two fates of daughter cells after stem cell division?

A

One maintains stem properties (self-renewal), while the other differentiates into a committed progenitor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the four classes of stem cells?

A

➡️ Totipotent (zygote) – any cell type.
➡️ Pluripotent (embryonic) – any germ layer.
➡️ Multipotent/Oligopotent – limited cell types.
➡️ Unipotent – one cell type.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Key historical milestones in stem cell research

A

➡️ 1968: First bone marrow transplant.
➡️ 1978: Cord blood stem cells discovered.
➡️ 1981: First mouse embryonic stem cell line.
➡️ 1995: First human embryonic stem cell line.
➡️ 1996: Dolly the sheep cloned.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How are cancer stem cells (CSCs) identified?

A

First identified in human acute myeloid leukaemia by John Dick’s team (1994).
➡️ Defined by their ability to repopulate leukaemia in immunocompromised mice.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the classical stochastic model of cancer?

A

Any cell can become cancerous and propagate the tumour. Cancer develops via clonal selection and Darwinian evolution.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the cancer stem cell (CSC) model?

A

Cancer arises in cells with stem-like properties, forming a hierarchical tumour structure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the Vogelstein model of cancer incidence?

A

Cancer incidence is proportional to the number of stem cell divisions in a tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Key markers of cancer stem cells (CSCs) in leukaemia?

A

CD34+CD38−

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What CSC markers are found in prostate cancer?

A

CD44+, a2B1high, CD133+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What CSC markers are found in colon cancer?

A

CD133+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is CD133 and why is it important?

A

A transmembrane glycoprotein that regulates pathways associated with stemness and drug resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What CSC markers are found in multiple myeloma?

A

CD138+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How can cancer stem cells be isolated?

A

Colony formation assays, serial transplantation in mice, lineage tracing/ablation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is colony formation used to identify CSCs?

A

CSCs form colonies from single cells, retaining clonogenicity through serial passage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the limitations of in vitro colony formation assays?

A

Tumour microenvironment, expensive cytokines, need for feeder layers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How is in vivo transplantation used to identify CSCs?

A

CSCs form tumours in immunocompromised mice and can be serially transplanted.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is lineage tracing?

A

CSC-specific labelling tracks their fate during tumour progression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is lineage ablation?

A

CSCs are selectively eliminated to test their role in tumour maintenance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Why are CSC-targeted therapies necessary?

A

Conventional therapies shrink tumours but do not eliminate CSCs, leading to regrowth.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How does CD44 contribute to drug resistance?

A

CD44 interacts with P-gp, promoting chemoresistance and tumour cell invasion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is one method of targeting CD133+ CSCs?

A

Anti-CD133 antibody linked to nanoparticle-loaded paclitaxel (PT).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How does a bi-specific anti-CD133/CD16 antibody work?

A

Forms an immune bridge with CD16+ natural killer cells, triggering antibody-dependent cell-mediated cytotoxicity (ADCC).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How can normal stem cells be protected during cancer treatment?

A

Selective targeting of cancer stem cell markers (e.g., CD133, CD44) while sparing normal stem cells.

25
Q

What is cancer cell plasticity?

A

The ability of cancer cells to change phenotype without genetic mutation.

26
Q

How does cancer cell plasticity contribute to drug resistance?

A

Allows cells to evade therapy, modify the microenvironment, and resist immune attacks.

27
Q

What is epithelial-mesenchymal transition (EMT)?

A

A process where epithelial cells lose polarity and gain a mesenchymal, migratory phenotype.

28
Q

How does EMT contribute to cancer progression?

A

EMT correlates with high tumour grade, invasion, and metastasis.

29
Q

What molecular changes drive EMT?

A

E-cadherin downregulation, Zinc (Zn2+)-induced migration and invasion.

30
Q

What is the reverse process of EMT?

A

Mesenchymal-to-epithelial transition (MET).

31
Q

How do pre-existing mutations drive therapy resistance?

A

Mutant tumour cells survive therapy and proliferate, leading to relapse.

32
Q

How do therapy-induced mutations drive resistance?

A

Treatment causes new mutations, leading to the emergence of resistant clones.

33
Q

How is EMT linked to therapy resistance?

A

Mesenchymal cancer cells are more chemoresistant and resist immune attacks.

34
Q

What role does the tumour microenvironment play in resistance?

A

Becomes immune-suppressive, reducing cytotoxic T-cell efficacy.

35
Q

How does cancer cell dormancy contribute to resistance?

A

Some cancer cells enter a drug-tolerant dormant state and reactivate after therapy.

36
Q

Can cancer cells be reprogrammed to reduce malignancy?

A

Yes, transcriptional reprogramming can alter their state to increase susceptibility to treatment.

37
Q

Example of plasticity-based therapy: Acute promyelocytic leukaemia

A

Treatment with retinoic acid overcomes transcriptional repression of RARA genes, restoring differentiation.

38
Q

Why is tumour heterogeneity a challenge for treatment?

A

Cancer evolves through mutation and plasticity, making it highly adaptable.

39
Q

What are the five stages of tumour evolution?

A

Initiation → Progression → Presentation → Remission → Relapse.

40
Q

What is the key difference between multipotent and oligopotent stem cells?

A

Multipotent cells can differentiate into multiple cell types, while oligopotent cells can only differentiate into a few closely related types.

41
Q

What are the limitations of stem cell therapies?

A

Ethical concerns, immune rejection, tumorigenic potential, difficulty in differentiation control.

42
Q

What are the challenges in identifying cancer stem cells (CSCs)?

A

Heterogeneity in marker expression, variations across cancer types, influence of tumour microenvironment.

43
Q

What is the role of self-renewal in CSCs?

A

CSCs self-renew through asymmetric division, allowing tumour maintenance and resistance.

44
Q

How do CSCs contribute to metastasis?

A

CSCs survive in circulation, adapt to new environments, and initiate secondary tumours at distant sites.

45
Q

What is the hierarchy of leukaemia stem cells (LSCs)?

A

HSC (SRC) → LSC (SL-IC) → Leukemic LTC-IC → Leukemic CFU → Leukemic blast cells → unregulated proliferation.

46
Q

What is the role of haematopoietic stem cells (HSCs) in leukaemia?

A

HSCs may acquire mutations that lead to the transformation into leukaemic stem cells (LSCs).

47
Q

What is the function of ABCG2 in CSCs?

A

ABCG2 is an efflux transporter that contributes to drug resistance by expelling chemotherapy drugs.

48
Q

What is ALDH and why is it significant in CSCs?

A

ALDH is an enzyme that detoxifies reactive oxygen species and is associated with chemoresistance and stem-like properties.

49
Q

What is the significance of CD90 in gliomas and liver cancer?

A

CD90 is a marker of CSCs that promotes tumour progression and invasiveness.

50
Q

Why is serial transplantation a gold standard for CSC identification?

A

It demonstrates self-renewal by showing that a small CSC population can generate new tumours across multiple generations of mice.

51
Q

What is a limitation of lineage tracing in CSC studies?

A

Tracking is complex in heterogeneous tumours, and marker expression may change over time.

52
Q

What are the key transcription factors driving EMT?

A

SNAIL, TWIST, ZEB1/ZEB2 – repress E-cadherin, promote invasion and metastasis.

53
Q

How does EMT influence immune evasion?

A

EMT reduces tumour antigen expression, making cancer cells less visible to immune cells.

54
Q

What is the MET process in metastasis?

A

Mesenchymal cells revert back to epithelial cells (MET) to colonise distant organs.

55
Q

How does the tumour microenvironment contribute to resistance?

A

Hypoxia, inflammatory signals, and stromal interactions enhance CSC survival.

56
Q

What is drug-tolerant persister (DTP) cell state?

A

A reversible, low-proliferation state that allows CSCs to survive therapy and reinitiate growth.

57
Q

What is one strategy for targeting plasticity in therapy-resistant cancers?

A

Differentiation therapy, forcing CSCs to become mature, non-dividing cells.

58
Q

What is an example of differentiation therapy?

A

Acute promyelocytic leukaemia (APL) treated with all-trans retinoic acid (ATRA) to induce differentiation.

59
Q

What is one approach to reprogramming cancer cells for treatment?

A

Epigenetic drugs can alter gene expression and force tumour cells into a more treatable state.